Yr Athro Richard Adams

B.Med.Sci, BM BS, MRCP, FRCR, MD

Clinical Reader

: adamsra3@cardiff.ac.uk
: Neuadd Meirionnydd, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS

: Ar gael fel goruchwyliwr ôl-raddedig

Richard Adams is Professor and Honorary Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is Director of Cancer Trials for the Centre for Trials Research and Director of the Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute anorectal cancer and CTRad WS2 (UK radiotherapy research) subgroups. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD.

Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D and F trials. He leads on the radiotherapy quality assurance programme for the UK ARISTOTLE and SAILOR trials. He has a role within Wales to engage researchers in translational research and leads work package 3 of the Wales Cancer Research Centre. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Sierra Leone Cancer Care link..

2020

Barber, P. R.et al. 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112(9), pp. 944-954. (10.1093/jnci/djz231)
Karapetis, C. S.et al. 2020. 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database. Annals of Oncology 31(S4), article number: S426. (10.1016/j.annonc.2020.08.545)
Papamichael, D.et al. 2020. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology 31, article number: S425. (10.1016/j.annonc.2020.08.543)

2019

Joharatnam-Hogan, N.et al. 2019. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology 4(11), pp. 854-862. (10.1016/S2468-1253(19)30289-4)
Gilbert, A.et al. 2019. 535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Annals of Oncology 30(S5), pp. v203-v204. (10.1093/annonc/mdz246.013)

2018

Fish, R.et al. 2018. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterology and Hepatology 3(12), pp. 865-873. (10.1016/S2468-1253(18)30264-4)
Elwood, P.et al. 2018. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE 13(9), pp. e0203957. (10.1371/journal.pone.0203957)
West, H.et al. 2018. Role for nucleotide excision repair gene variants in oxaliplatin-induced peripheral neuropathy. JCO Precision Oncology 2, pp. 1-18. (10.1200/PO.18.00090)
Rao, S.et al. 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII715-VIII716., (10.1093/annonc/mdy424.022)
Madi, A.et al. 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII22., (10.1093/annonc/mdy269.072)
Madi, A.et al. 2018. Pharmacogenetic analyses of 2,183 patients with advanced colorectal cancer; Potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.. European Journal of Cancer 102, pp. 31-39. (10.1016/j.ejca.2018.07.009)
Goey, K. K.et al. 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer 100, pp. 35-45. (10.1016/j.ejca.2018.05.010)
Gollins, S.et al. 2018. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer (10.1038/s41416-018-0209-4)
Jones, C. M.et al. 2018. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. International Journal of Radiation Oncology - Biology - Physics 101(5), pp. 1202-1211. (10.1016/j.ijrobp.2018.04.033)
Sjoquist, K. M.et al. 2018. Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project. JNCI: Journal of the National Cancer Institute 110(6), pp. 638-648. (10.1093/jnci/djx253)
Rose, G.et al. 2018. The cardiopulmonary exercise test grey zone; optimising fitness stratification by application of critical difference. British Journal of Anaesthesia 120(6), pp. 1187-1194. (10.1016/j.bja.2018.02.062)
Alderdice, M.et al. 2018. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology 245(1), pp. 19-28. (10.1002/path.5051)

2017

Scurr, M.et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
Scurr, M. J.et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
Scurr, M.et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
Seligmann, J.et al. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology 28(3), pp. 562-568. (10.1093/annonc/mdw645)
Adams, R. 2017. Surveillance of anal canal cancers. Surgical Oncology Clinics of North America 26(1), pp. 127-132. (10.1016/j.soc.2016.07.007)
Wood, G.et al. 2017. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs 28(5), pp. 546-550. (10.1097/CAD.0000000000000488)

2016

Franko, J.et al. 2016. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 17(12), pp. 1709-1719. (10.1016/S1470-2045(16)30500-9)
Muirhead, R.et al. 2016. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology 29(3), pp. 188-197. (10.1016/j.clon.2016.10.005)
Weber, A. M.et al. 2016. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget 7(38), pp. 60807-60822. (10.18632/oncotarget.11845)
Sharma, R. A.et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
Hendry, M.et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205)
Ciardiello, F.et al. 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21(3), pp. 292-300. (10.1634/theoncologist.2015-0279)
Morris, E. J. A.et al. 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28(8), pp. 522-531. (10.1016/j.clon.2016.02.002)
Grenader, T.et al. 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114(6), pp. 612-615. (10.1038/bjc.2016.23)
Renfro, L. A.et al. 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34(2), pp. 144-150. (10.1200/JCO.2015.61.6441)
Hubbard, G.et al. 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6(1), article number: e009284. (10.1136/bmjopen-2015-009284)

2015

Richman, S. D.et al. 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69(1), pp. 35-41. (10.1136/jclinpath-2015-203097)
Hutchinson, R. A.et al. 2015. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine 13, article number: 217. (10.1186/s12967-015-0531-z)
Shi, Q.et al. 2015. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33(1), pp. 22-28. (10.1200/JCO.2014.56.5887)

2014

Baillie, J.et al. 2014. Developing meaningful public involvement in a cancer clinical trials unit. Presented at: COMET IV Meeting: Core Outcome Measures in Effectiveness Trials, Rome, Italy, 20-21 November 2014.
Muirhead, R.et al. 2014. Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
Glynne-Jones, R.et al. 2014. End points in anal cancer: hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
Maughan, T.et al. 2014. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine?. British Journal of Cancer 110, pp. 2178-2186. (10.1038/bjc.2014.182)
Munro, J.et al. 2014. CRIB-the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)

2013

Smith, C.et al. 2013. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 19(15), pp. 4104-4113. (10.1158/1078-0432.CCR-12-2581)
Smith, C.et al. 2013. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation 34(7), pp. 1026-1034. (10.1002/humu.22333)
Glynne-Jones, R.et al. 2013. Prognostic factors for recurrence and survival in anal cancer. Cancer 119(4), pp. 748-755. (10.1002/cncr.27825)
Türbachova, I.et al. 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8(11), pp. 1226-1235. (10.4161/epi.26334)

2012

Vale, C. L.et al. 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38(6), pp. 618-625. (10.1016/j.ctrv.2011.11.002)
Dunlop, M. G.et al. 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk [Letter]. Nature Genetics 44(7), pp. 770-776. (10.1038/ng.2293)
Gwynne, S. H.et al. 2012. Image-guided Radiotherapy for Rectal Cancer - A Systematic Review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
Gwynne, S. H.et al. 2012. Imaging for Target Volume Delineation in Rectal Cancer Radiotherapy - A Systematic Review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)

2011

Glynne-Jones, R.et al. 2011. "Mind the gap" - The impact of variations in the duration of the treatment gap and overall treatment time in the first UK anal cancer trial (ACT I). International Journal of Radiation Oncology*Biology*Physics 81(5), pp. 1488-1494. (10.1016/j.ijrobp.2010.07.1995)
Maughan, T. S.et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 377(9783), pp. 2103-2114. (10.1016/S0140-6736(11)60613-2)
Adams, R. A.et al. 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 12(7), pp. 642-653. (10.1016/S1470-2045(11)70102-4)
Shaw, P. and Adams, R. A. 2011. Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11(10), pp. 1543-1553. (10.1586/era.11.143)

2010

Maughan, T. S.et al. 2010. Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option [Letter]. Journal of Clinical Oncology 28(17), pp. e275-e276. (10.1200/JCO.2009.27.8218)

2009

Adams, R. A.et al. 2009. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 100(2), pp. 251-258. (10.1038/sj.bjc.6604877)
Wadhawan, A., Stephens, R. and Adams, R. A. 2009. Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 9(1), pp. 125-134. (10.1586/14737140.9.1.125)
Morgan, M. A.et al. 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96(11), pp. 1300-1307. (10.1002/bjs.6705)

2008

Adams, R. A.et al. 2008. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy 8(8), pp. 1237-1245. (10.1586/14737140.8.8.1237)

2007

Shaw, P.et al. 2007. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 19(1), pp. 87-95. (10.1016/j.clon.2006.09.009)

1993

Hardie, K. R., Adams, R. A. and Towner, K. J. 1993. Transferrin-binding ability of invasive and commensal isolates of Haemophilus spp.. Journal of Medical Microbiology 39(3), pp. 218-224. (10.1099/00222615-39-3-218)

Proffiliau allanol

ORCID